Mr. James Meikle reports

EUPRAXIA PHARMACEUTICALS ANNOUNCES VOTING RESULTS FROM ANNUAL GENERAL MEETING OF SHAREHOLDERS

Eupraxia Pharmaceuticals Inc. has released the results from its annual general meeting of shareholders held on June 18, 2026.

Pursuant to a resolution passed by ballot vote, all of the seven nominees proposed by management for election to the company's board of directors at the meeting and listed in the company's management information circular dated May 11, 2026, were elected. The directors will remain in office until the next annual meeting of shareholders, or until their successors are elected or appointed.

The results of the vote on the election of the board are as shown in the attached table.

The other item of business at the meeting was to reappoint KPMG LLP as the auditor of the company for the ensuing year and to authorize the board to fix the remuneration of the auditor. All items of business were passed by the shareholders at the meeting.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere, a proprietary, polymer-based microsphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyperlocalized fashion, targeting only the tissues that physicians are wanting to treat. The company believes the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere technology platform has the potential to augment and transform existing Food and Drug Administration-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a phase 1b/2 trial, the Resolve trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a phase 2b clinical trial (Springboard) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary end point and three of the four secondary end points. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

We seek Safe Harbor.